The board of Sudarshan Pharma Industries at their meeting held on 5 September 2026, inter-alia, approved to acquire 24,23,675.64 equity shares of common stock, par value US$0.0001 per share of MedTherapy Biotechnology Inc., a corporation incorporated under the laws of the State of Delaware, equivalent to 9.50% of the issued and outstanding share capital of the Company.
Board of Sudarshan approves acquisition of 9.50% stake in MedTherapy Biotechnology Inc.
The board of Sudarshan Pharma Industries at their meeting held on 5 September 2026, inter-alia, approved to acquire 24,23,675.64 equity shares of com...
By Dhallo News · September 7, 2026 at 1:04 PM IST
SOURCE: Business Standard - Politics
ORIGINAL REPORT: Click here
DHALLO EDITORIAL STATUS: Aggregated & reviewed
Have feedback on this article?Report error or suggestion